Related Experiment Video

Updated: Dec 17, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.0K

Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma

Kyrollis Attalla1, Stanley Weng1, Martin H Voss1

  • 1Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, 353 East 68th Street, 5th Floor, New York, NY 10065, USA.

The Urologic Clinics of North America
|July 1, 2020
PubMed

Insights

Advances in targeted agents and immunotherapy have improved metastatic renal cell carcinoma (mRCC) management. However, challenges remain, necessitating better risk-stratification tools and biomarkers for improved patient survival in mRCC.

Area of Science:

  • Oncology
  • Translational Medicine

Background:

  • Metastatic renal cell carcinoma (mRCC) management has seen significant progress over the last 20 years.
  • Novel targeted agents and a deeper understanding of mRCC molecular biology have emerged.
  • Recent advancements include immune checkpoint blockade therapies, showing promise in mRCC treatment.

Purpose of the Study:

  • To review current risk-stratification tools for patients with mRCC.
  • To discuss investigated predictive and prognostic biomarkers in mRCC.
  • To provide an overview of recent therapeutic milestones in mRCC management.

Main Methods:

  • Literature review of recent advancements in mRCC treatment.
  • Analysis of targeted agents and immunotherapy in mRCC.
  • Examination of risk-stratification tools and biomarkers for mRCC.

Main Results:

  • Despite progress, mRCC treatment remains challenging with modest survival benefits.
  • Novel targeted therapies and immunotherapies represent significant strides.
  • Risk-stratification tools and biomarkers are crucial for optimizing mRCC patient care.

Conclusions:

  • Continued research into risk-stratification and biomarkers is essential for improving mRCC outcomes.
  • Personalized treatment strategies are key to overcoming challenges in mRCC management.
  • Integrating novel agents and biomarkers offers the best path forward for mRCC patients.
Keywords:
ImmunotherapyMetastatic renal cell carcinomaPredictive biomarkerPrognostic biomarkerRisk assessmentTargeted therapy

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.0K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.8K

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
193
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
572
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
331
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
256
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
216
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
103